University of Helsinki
Klefström lab
Oncogenic signaling pathways as therapeutic targets in breast cancer
Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer.
News
Lab Retreat 2017
The annual Klefström research group lab retreat took place at Serena waterpark on February 2017. The two-day lab retreat inspired scientific discussions and debates across a wide range of cancer-related topics. After the scientific presentations of the day, KlefaLab members enjoyed a wonderful dinner in ‘Kota’ and cheerful live music. On the second day, the group discussed the lab management issues and came up with ideas on how to enhance interactions and collaborations within a research group.
Klefström lab on facebook
One Matrix to rule them all 🌊
physics.aalto.fi/en/current/news/2017-06-14-002/#.WUF3T7Hbh2Y.linkedin
News: Novel 3D matrix will allow predictive and effective breast cancer treatment
physics.aalto.fi
The extracellular matrix keeps the structure of the tumor tissues unchanged and thereby allows correct and personalized drug identification.
Dear Colleagues and everybody,
Please save the date for THIS WEEK’S FRIDAY talk of Prof. Gerard Evan (FRS) from University of Cambridge.
Special Seminar
Time: 09.06.2017 at 11:00 -11.45 AM
Place: Biomedicum Helsinki, Lecture Hall 1
Prof. Gerard Evan, University of Cambridge
Taking the MYC out of cancer
For further information: www.cancerresearchuk.org/our-research/researchers/professor-gerard-evan
Host: Juha Klefström (helsinki.fi)
Professor Gerard Evan is a foremost cancer researcher, whose work on MYC cancer gene has many times overturned established thinking, leading to a massive advances in our understanding of the intricate mechanisms that drive cancer and paving the way for new treatments. Just to name few examples - establishing the apoptotic function of MYC (Cell 1992), formulating the concept of intrinsic tumor suppression (together with S.Lowe and others 2004 PMID: 15549092), non-redundant cancer pathways (in vivo MYC-dependence of RAS cancer pathway in 2013 PMID: 23475959 ), as well as exposing many aspects of the interplay between the cellular oncogenes and cancer relevant alterations of tumor microenvironment, including tumor immunity (PMID: 21478273 and unpubl.). In addition to being a superb cancer scientist, Gerard has been fertilizing the field for over 30 years with "a thought off the beaten track”, leading to radically new concepts in cancer research and markedly forwarding global efforts to cure cancer one day.
attachment
www.youtube.com/watch?v=G0D29CO2Lq4
cancerresearchuk.org
Professor Gerard Evan and his team in the Department of Biochemistry at the University of Cambridge are studying the genes that drive the development and growth of cancer, called oncogenes.
Take home message: Rational (science based) combination therapies to cancer! Most clinical combinations irrational. mkfz.charite.de/en/news/conferences/nvic_2017/program/ …
Molekulares Krebsforschungszentrum: - Charité - Universitätsmedizin Berlin: Program
mkfz.charite.de
Information on the range of services at Charité - Universtätsmedizin Berlin for patients, physicians, students and scientists
Several Researcher and a Project Coordinator Position Available in Klefström Laboratory, Research Programs Unit, University of Helsinki
The laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer. We are now seeking an energetic postdoc and a graduate student (or late stage pro gradu student) for a TEKES and the Academy of Finland funded project aiming to build a preclinical platform on patient-derived breast cancer explants. The project offers an opportunity to learn about new concepts and methods in modern cancer biology, including patient-derived organoids, targeted therapies and immuno-oncology, as well as push the limits of predictive cancer models with an ultimate goal to help breast cancer patients already within the lifetime of the project. In addition, one project coordinator position is open in FuGU with an affiliation with Klefström lab.
For more information on the open positions and application procedures, please visit:
www.helsinki.fi/en/researchgroups/cancer-cell-circuitry-laboratory
Deadline for application is June, 15.
Cancer Cell Circuitry Laboratory | University of Helsinki
helsinki.fi
Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer. Our current research specifically focuses on therapeutic strategies aiming to exploit MYC oncogene-induced vulnerabilities and therapeutically int...
Jobs! KlefströmLab & FuGu klefstromlab.com/home/open-positions/